<DOC>
	<DOCNO>NCT02185781</DOCNO>
	<brief_summary>The present study aim study safe tolerable new therapy patient Acute Lymphoblastic Leukemia ( ALL ) . This new therapy consist immunotherapy , approach focus immune system , target ALL patient complete remission may still disease cellular level ( call 'minimal residual disease ' ) . For information , please , discuss treat physician .</brief_summary>
	<brief_title>Phase I Study Adoptive Immunotherapy With Enriched Expanded Autologous Natural Killer ( NK ) Cells Patients With Ph+ Acute Lymphoblastic Leukemia ( ALL )</brief_title>
	<detailed_description>This open label , multicenter , phase I study adoptive immunotherapy enrich expand autologous natural killer ( NK ) cell patient Ph+ acute lymphoblastic leukemia ( ALL ) complete hematologic remission ( CHR ) persistent/recurrent minimal residual disease ( MRD ) ≥60 year eligible post-CHR treatment modality . The study investigate safety tolerability new type NK-based immunotherapy base infusion escalate dos ex-vivo expand autologous NK cell Ph+ ALL patient . A maximum 6 patient enrol two different step . No conditioning therapy administer infusion expand NK cell . Patients may receive tyrosine kinase inhibitor ( TKI ) maintenance .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Neoplasm , Residual</mesh_term>
	<criteria>Adult subject Ph+ ALL CHR ( 1st 2nd ) MRD positivity confirm baseline , old equal 60 year eligible postCHR treatment modality . WHO score 01 . Hematopoietic , liver renal normal function define follow : WBC big equal 2.000/mm3 lymphocyte big equal 500/mm3 neutrophil big equal 1.000/mm3 platelet big equal 50.000/mm3 Hb big equal 9 g/dl creatinine few equal 1.5 x ULN bilirubin few equal 1.5 x ULN AST ALT less 3 time upper limit normal . LDH less 2 time upper limit normal . For male female subject childbearing potential , agreement use effective contraception . Authorization Istituto Superiore di Sanità ( ISS ) accord DM 2 March 2004 . Signed write informed consent accord ICH/EU/GCP national local regulation . Concurrent chemotherapy immunotherapy ( TKI maintenance permit ) . Any contraindication perform leukapheretic procedure mononuclear cell collection . Active chronic infection , include Treponema , HIV , HBV and/or HCV unless antigen/PCR negative . Presence autoimmune symptom . Pregnant lactating female . Simultaneous participation another clinical trial . Any physical psychological impediment patient could lead investigator suspect his/her poor compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Adoptive immunotherapy</keyword>
	<keyword>Enriched expand autologous natural killer ( NK ) cell</keyword>
	<keyword>Ph+ acute lymphoblastic leukemia</keyword>
	<keyword>≥60 year</keyword>
	<keyword>Not eligible post-CHR treatment modality</keyword>
</DOC>